TrialOpen forum infectious diseases2026

Rapid Virologic Suppression With Dolutegravir Plus Lamivudine Facilitates Early Switch to Long-Acting Cabotegravir Plus Rilpivirine for Treatment-Naive People With HIV-1: Month 11/12 Outcomes From the Phase 3b VOLITION Study.

Ezequiel Córdova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.